Patients with anaplastic lymphoma kinase-positive (ALK D ) advanced nonesmall-cell lung cancer should benefit from targeted therapy. The effect of increased use of an immunohistochemical technique was estimated using a health careeeconomics analysis. Extensive use of D5F3 has resulted in a diagnostic costs decrease. These savings could be reinvested to test a greater number of patients (53% vs. 75%). Reinvesting the saving would lead to an overall survival gain (D20%). Background: To ensure identification of anaplastic lymphoma kinase-positive (ALK þ ) patients, the Italian Drug Agency suggested a testing algorithm based on the use of fluorescence in situ hybridization (FISH) and/or immunohistochemistry. The aim was to evaluate the clinical and economic effects of adopting an immunohistochemical test (Ventana ALK D5F3) as an option for detecting ALK protein expression in advanced nonesmall cell lung cancer (NSCLC) patients. Materials and Methods: A budget impact model was developed by adopting the Italian National Health Service (NHS) perspective and a 5-year period to compare 2 scenarios: the current use of D5F3 (28%; current scenario) and increased use of D5F3 (60%; alternative scenario). The testing cost and the number and cost of the identified ALK þ patients were evaluated. Results: A more extensive use of D5F3 in the alternative scenario showed a decrease in diagnostic costs of wV468,000 compared with current scenario when considering all advanced NSCLC patients. If these savings were allocated to test more NSCLC patients (75% vs. 53%), an incremental cost per identified ALK þ patient of V63 would be required, leading to an overall survival gain for the alternative scenario compared with the current scenario (32.4 vs. 27.1 months; relative increase, 20%). Conclusion: The use of D5F3 would provide a cost savings for the NHS owing to a lower acquisition cost than FISH and a comparable detection rate. The savings could be reinvested to test a greater number of patients, leading to more efficient identification, use of targeted therapy, and improvement in clinical outcomes of ALK þ patients.
Introduction
Lung cancer is 1 of the most common tumor types (the fourth prevalent in Italy, accounting for 11% of total cancer cases diagnosed) and, by far, the leading cause of cancer death among both men and women. 1 Lung cancer consists of 2 major types:
nonesmall cell lung cancer (NSCLC; 85% of lung tumors) and small-cell lung cancer (SCLC; 15% of lung tumors). 1 In recent years, a major paradigm shift has occurred in the management of NSCLC. NSCLC can be now subclassified by the histologic features and driver mutation, if known or present. 2 In the past decade, relevant efforts have addressed the detection of mutations in the epidermal growth factor receptor (EGFR) and the abnormal fusion of anaplastic lymphoma kinase (ALK). 2 It has been estimated that 4% of NSCLCs will have a rearrangement in the ALK gene. 1 This genetic rearrangement is most often observed in nonsmokers (or light smokers) with adenocarcinoma of NSCLC. The ALK gene rearrangement produces an abnormal ALK protein that causes the cells to grow and spread. 3 Detection of an ALK mutation is key to treating NSCLC patients with crizotinib, to date the only ALK-targeted therapy approved in Italy, which has recently received an extension of reimbursement for the treatment of newly diagnosed ALK þ NSCLC patients. 4 Several diagnostic technologies have been introduced to detect ALK rearrangements. For several years, fluorescence in situ hybridization (FISH) has been considered the reference standard for detecting tumors carrying an ALK rearrangement. However, the increasing compelling evidence shown by immunohistochemistry (IHC) in recent years has increased the diagnostic opportunities for ALK detection, offering health care professionals an efficient tool to determine the treatment choices. 5 In its guidelines for crizotinib reimbursement, the Italian Drug Agency (AIFA) has referenced both FISH and IHC as recommended tests for the detection of ALK þ tumors. 6 More specifically, the IHC tests AIFA has recommended include Ventana ALK (D5F3) CDx (Ventana; recently developed by Roche Diagnostics), ALK1 (Dako), and ALK 5A4 (Abcam).
The Ventana results are interpreted using a binary scoring system (positive vs. negative), which has been found to be an efficient predictor of ALK inhibition outcome, tumor response, and survival. 7 Unlike Ventana, ALK1 (Dako) and ALK 5A4 (Abcam) provide 4 possible results: 0 in the case of absent ALK protein expression; 1þ or 2þ in the case of uncertain results; and 3þ in the case of ALK protein expression. For ALK1 (Dako) and ALK 5A4 (Abcam), confirmation by 1 type of FISH test is required if a 1þ or 2þ result is obtained, which requires time and could delay treatment and increase test costs. The objective of the present analysis was to evaluate the clinical and economic effects of the adoption of the Ventana test. The recent extension of reimbursement conditions for crizotinib and the expected introduction of new ALK targeted agents (eg, alectinib, ceritinib, brigatinib, and lorlatinib) will increase the adoption of ALK testing. 8 Therefore, technological assessments of the diagnostic tools available in this area would inform policy makers regarding the cost-effectiveness and economic sustainability of the alternative options.
Materials and Methods

Study Design and Parameters
A budget impact/cost-effectiveness analysis was performed to estimate the annual number of NSCLC patients who could be tested for ALK status in Italy and to evaluate the costs and clinical consequences of testing and treating such patients. More specifically, we aimed to verify whether increasing adoption of Ventana would be cost-effective and economically sustainable for the Italian National Health Service (NHS). The analysis was run using a Microsoft Excel 2016 decisional-analytical model. The first step of the analysis consisted of estimating the ALK testeeligible population (ie, number of patients with advanced NSCLC assumed to be new patients and then requiring genetic testing to select optimal treatment). The eligible population was then converted into the tested population, using assumptions on testing rates (ie, proportion of patients with access to the ALK test). The tested population was stratified into ALK þ and ALK À cases (4% and 96% of cases, respectively). 1 It was assumed that NSCLC patients tested for ALK status would have simultaneously received EGFR testing. Driven by the test results, the patients received ad hoc treatment (first and second line). The reasoning behind the model was the underlying assumption that tests ensuring better diagnostic accuracy (ie, high sensitivity and specificity) would also ensure more efficient treatment. High-sensitivity tests, for example, will reduce the number of false-negative cases (ie, ALK þ patients who would not receive targeted therapy because ALK positivity was not detected). In contrast, high-specificity tests will reduce the number of false-positive cases (ie, ALK À patients with erroneously detected positive status receiving ineffective targeted therapy). The analysis was conducted by adopting the Italian NHS perspective and a period of 5 years. Consistent with the adopted perspective, only direct costs were evaluated: diagnosis costs, treatment costs, administration costs, and costs for the management of adverse events (AEs). The economic effect of Ventana was determined by comparing 2 scenarios: the current scenario (current use of Ventana) versus an alternative scenario (with increased use of Ventana). The analysis determined the costs and outcomes of both the entire cohort of advanced NSCLC-tested patients and the ALK þ subgroup (4% of the advanced NSCLC population). For the clinical outcomes, the model estimated overall survival (OS) and progression-free survival (PFS) of such cohorts, both depending on the treatment selected for each patient on the basis of the test results. Two analyses were performed. In the base analysis in which, accounting for 53% of patients with newly diagnosed advanced NSCLC had access to ALK testing, the distribution of the patients in the current scenario was compared with that in the alternative scenario (Table 1) . 9 In the second analysis, the reinvestment analysis, in which the distribution of patients in the current scenario applied to a test access rate of 53% was compared with the distribution of patients in the alternative scenario applied to a test access rate of 75%. 
Estimation of Eligible Population and Use of ALK Tests
To estimate the ALK test eligible population and the split between ALK þ and ALK À patients, Italian epidemiologic sources and references from international studies were combined ( Table 2) . The data refer to the ALK þ population (more details on the overall population of advanced NSCLC patients are provided in Supplemental Table 1 ; available in the online version). For both analyses, the mix of testing options was derived from market data 15 (Table 1) . Such data suggest that in current practice, FISH tests remain the diagnostic standard for ALK testing (43% of tests), with IHC testing increasingly used compared with previously.
Diagnostic Accuracy
From a review of the reported data, 16 Vysis, Dako, Zytovision, and Kreatech were selected as the main FISH alternatives and were included in the model. For the IHC tests, the alternatives recommended by AIFA to test ALK status (and eventually initiate treatment with crizotinib) 6 were considered: ALK1 (Dako) and ALK 5A4 (Abcam). The sensitivity and specificity were derived from the reported data (Table 3 ). The data used for FISH were the weighted averages of the data reported by Marchetti et al 16 for the 4 tests: Vysis, Dako, Zytovision, and Kreatech. For the IHC tests, the sensitivity and specificity were calculated with respect to the FISH performance and as reported by Le Quesne et al. 17 The original data reported by Le Quesne et al 17 were then corrected using the data Additional assumptions were implemented in the model. These included that, first, 3% of ALK1 (Dako) and ALK 5A4 (Abcam) would require FISH confirmation 6 ; second, 10% of the samples analyzed using FISH would contain insufficient tissue. 18 In the presence of insufficient tissue, a second test, the same as the first used, would then be performed.
Clinical and Economic Data
For both scenarios, the number of true-positive (TP), false-positive (FP), true-negative, and false-negative (FN) test results was determined using the model. These data are dependent on the sensitivity and specificity of the test ( Table 4 . Some other assumptions were implemented for the 5-year simulation period: (1) patients reaching the median PFS will develop progression and switch to second-line therapy; (2) patients reaching the median PFS of secondline treatment will develop progression and switch to third-line therapy; and (3) patients reaching the median OS will die and be removed from the model. Diagnostic inaccuracy has a negative effect on the cost-effectiveness of pharmacologic treatments. Thus, FN patients would not receive targeted therapy and would be assigned to the EGFR þ , squamous or nonsquamous, subgroup, with the probabilities listed previously (the PFS and OS data for each subgroup are listed in Table 4 ). Second, FP patients would be treated with targeted therapy (generally at a greater cost than nontargeted therapy) but without the expected benefit (average PFS and OS of therapies other than crizotinib). The therapies adopted for each indication and the related costs and PFS and OS data are listed in Table 4 . The treatment costs (Table 4) were calculated using standard dosage schemes reported in Summary Product Characteristics documents, the ex-manufacturer prices negotiated in Italy, 39 and full wastage hypotheses (ie, the residual amount of an active substance to treat a patient is not used to treat the next patient). Administration costs were calculated assuming that oral therapy did not require any administration costs and that 70% of infusion therapies were administered using a day-hospital regimen 21 (Diagnosis-Related Group [DRG] code, 410), and 30% were administered using an outpatient regimen 22 (DRG code, 99.25).
14 The costs for the management of treatment-related AEs were calculated using ambulatory tariffs 22 for any grade < 3 AEs and 6, 17 92.84% 100.00 ALK ALK1 (Dako) 6, 17 88.79% 100.00 ALK 5A4 (Abcam) 6, 17 84.37% 100.00
Abbreviations: ALK ¼ anaplastic lymphoma kinase; FISH ¼ fluorescence in situ hybridization.
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14
Results
In the base analysis (53% of patients having access to the ALK test in the current and alternative scenarios), a total of 16,583 patients were tested, of whom 1252 were assumed to be ALK þ . A more extensive use of Ventana in the alternative scenario showed a decrease in ALK diagnostic costs of wV468,000 compared with the current scenario when considering all advanced NSCLC patients and wV19,000 when considering the ALK þ NSCLC patients only (base analysis; Supplemental Table 2 ; available in the online version). This resulted from the lower acquisition costs compared with those for FISH and a comparable ALK detection rate. If these savings plus additional investments were allocated to test more NSCLC patients (75% vs. 53% in the base analysis), the number of TP patients detected would increase from 616 to 868 (relative increase, þ41%) in the alternative scenario compared with the current scenario (Table 5 ; reinvestment analysis). Detecting a greater number of ALK þ patients would allow for improvement in the clinical outcomes, because a greater number of patients would be treated with crizotinib. When considering the ALK þ NSCLC patients, the OS would increase from 27 months per patient in the current scenario to 32 months per patient in the alternative scenario (relative increase, þ20%); and the PFS would increase from 11 months per patient in the current scenario to 13 months per patient in the alternative scenario (þ6%). Crizotinib is 1 of the most expensive treatments included in the present analysis. Thus, the total cost of treatment would increase in the alternative scenario compared with the current scenario but with an increase in efficacy. Nevertheless, when analyzing the cost-efficacy indicators (Table 6) , the expenditure required for an incremental unit of efficacy would be lower than the stated willingness to pay for treatment of Abbreviations: ALK þ ¼ anaplastic lymphoma kinase-positive; AS ¼ alternative scenario; CS ¼ current scenario; OS ¼ overall survival; PFS ¼ progression-free survival.
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Clinical Lung Cancer September 2018 -e739 oncologic disease. [41] [42] [43] Regarding the cohort of advanced ALK þ NSCLC patients, in the alternative scenario, an incremental expenditure of V63 per patient would allow the detection of 1 additional TP case; an incremental expenditure of V5194 per patient would result in 1 additional month of survival; and an incremental expenditure of V16,686 per patient would result in 1 additional month of PFS compared with the current scenario.
Discussion
IHC testing is an appropriate and reliable alternative to FISH for the identification of ALK þ NSCLC. 5, 44 The Ventana ALK (D5F3)
CDx assay was specifically developed to maximize agreement with ALK FISH testing and to enable the use of ALK IHC as a standalone companion diagnostic test to identify patients with ALK þ NSCLC eligible for treatment with crizotinib. 45 Moreover, it is also less labor-intensive, does not require specialized training, and, unlike FISH, does not require a minimum number of tumor cells to be present in the sample. The chemical detection used in the ALK (D5F3) CDx assay allows for a simple binary scoring algorithm that results in high reader-to-reader precision. 44 In the present analysis, the clinical utility of Ventana was evaluated in 2 scenarios: the current use of Ventana versus the increased use of Ventana. With a lower cost compared with FISH techniques, the adoption of Ventana would allow for the testing of a greater number of patients (hypothesis in the model, 53% vs. 75%). This would result in an increase in the number of TP cases detected (þ41%) and would improve the overall clinical outcomes of the cohort of patients with advanced ALK þ NSCLC (þ20% OS and þ6% PFS). The present analysis could have been affected by some limitations. First, the model was a simplification of the actual diagnostic and treatment pathway, which is quite complex for NSCLC because multiple options are available and the treatment decisions are driven by several considerations (eg, patient age and level of functioning, the need to optimize efficacy vs. safety, the level of caregiving). The model included the most representative options for each treatment line and tumor type; however, we know that other alternatives are available (eg, afatinib or erlotinib could be used as first-line treatment of EGFR þ patients; best supportive care could be replaced by other options for third-line treatment, such as compassionate use of experimental ALK-tyrosine kinase inhibitors for specific cases). Because our analysis did not focus on the treatment costs, we believe that considering only 1 treatment as representative of its class would not introduce significant bias. Second, the OS of patients receiving crizotinib was not reached in the clinical trial; thus, an estimation was used for the present analysis, which could have affected the results. Considering an OS equal to 75% of that used in the model (37.1 months) in the reinvestment analysis, the OS would increase from 25 months per patient in the current scenario to 30 months per patient in the alternative scenario (relative increase, þ18%). Also, an incremental expenditure of V5569 per patient would result in 1 additional month of survival. Finally, we used a method to convert IHC sensitivity and specificity versus FISH tests (which have been historically used as the diagnostic benchmark) into IHC sensitivity and specificity to the treatment response (ie, ALK TP patients with IHC will respond to crizotinib therapy). Despite the evidence that some ALK FISH À /ALK IHC þ cases will respond to crizotinib, such evidence requires confirmation by new studies. A recent study showed that the ALK (D5F3) CDx assay is superior to ALK-FISH on small biopsies and fine needle aspiration to predict the tumor response and survival to crizotinib for patients with advanced NSCLC. 7 
Conclusion
The Ventana ALK (D5F3) CDx assay is a suitable standalone test representing a relatively inexpensive alternative method to FISH to identify ALK þ NSCLC patients who could benefit from crizotinib treatment.
Clinical Practice Points
We decided to develop the present study because no other evidence was available to understand the cost-effectiveness of adopting different tests for ALK assessment. We implemented the research to understand how to guarantee the best budget and patient management.
Developing a budget impact model by adopting the Italian NHS perspective and a 5-year period, 2 scenarios were compared: current use of D5F3 (28%; current scenario) and increased use of D5F3 (60%; alternative scenario). The use of D5F3 would be cost saving for the NHS owing to an acquisition cost lower than that of FISH, with a comparable detection rate. Analysis of the alternative scenario highlighted a decrease in diagnostic costs of wV468,000 compared with the current scenario when considering all advanced NSCLC patients. Thereafter, these savings could be allocated to test more NSCLC patients (75% vs. 53%), with an incremental cost per identified ALK þ patient of V63 and an increase in the OS with the alternative scenario compared with the current scenario (32.4 vs. 27.1 months; relative increase, 20%). The savings could be reinvested to test a greater number of patients, leading to more efficient identification, greater use of target therapy, and improvements in the outcomes for ALK þ patients. Our study has provided an approach and a health economics model that could be useful to other countries to understand how the budget might be managed to guarantee the best patient management and maximize the clinical outcomes.
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